135 related articles for article (PubMed ID: 35779750)
21. Clinical Value of TXNDC12 Combined With IDH and 1p19q as Biomarkers for Prognosis of Glioma.
Wang X; Yang Q; Liu N; Bian Q; Gao M; Hou X
Pathol Oncol Res; 2021; 27():1609825. PubMed ID: 34629960
[No Abstract] [Full Text] [Related]
22. DNAJC10 correlates with tumor immune characteristics and predicts the prognosis of glioma patients.
Liu F; Tu Z; Liu J; Long X; Xiao B; Fang H; Huang K; Zhu X
Biosci Rep; 2022 Jan; 42(1):. PubMed ID: 34988580
[TBL] [Abstract][Full Text] [Related]
23. MELK is a prognostic biomarker and correlated with immune infiltration in glioma.
Yang H; Zhou H; Wang G; Tian L; Li H; Zhang Y; Xue X
Front Neurol; 2022; 13():977180. PubMed ID: 36353126
[TBL] [Abstract][Full Text] [Related]
24. MXRA5 Is a Novel Immune-Related Biomarker That Predicts Poor Prognosis in Glioma.
Sun JZ; Zhang JH; Li JB; Yuan F; Tong LQ; Wang XY; Chen LL; Fan XG; Zhang YM; Ren X; Zhang C; Yu SP; Yang XJ
Dis Markers; 2021; 2021():6680883. PubMed ID: 34211612
[TBL] [Abstract][Full Text] [Related]
25. Correlation of immune phenotype with IDH mutation in diffuse glioma.
Berghoff AS; Kiesel B; Widhalm G; Wilhelm D; Rajky O; Kurscheid S; Kresl P; Wöhrer A; Marosi C; Hegi ME; Preusser M
Neuro Oncol; 2017 Oct; 19(11):1460-1468. PubMed ID: 28531337
[TBL] [Abstract][Full Text] [Related]
26. High TRAF3IP3 Level Predicts Poor Prognosis of Patients with Gliomas.
Yang G; Tang S; Zhang J; Qin L
World Neurosurg; 2021 Apr; 148():e436-e449. PubMed ID: 33444836
[TBL] [Abstract][Full Text] [Related]
27. Identification of a Good-Prognosis IDH-Mutant-Like Population of Patients with Diffuse Gliomas.
Wang Z; Liu X; Wang Z; Bao Z; Zhang W; Zhang C; Jiang T
Curr Mol Med; 2018 Mar; 17(7):518-526. PubMed ID: 29437008
[TBL] [Abstract][Full Text] [Related]
28. O6-methylguanine DNA methyltransferase gene promoter methylation status in gliomas and its correlation with other molecular alterations: first Indian report with review of challenges for use in customized treatment.
Jha P; Suri V; Jain A; Sharma MC; Pathak P; Jha P; Srivastava A; Suri A; Gupta D; Chosdol K; Chattopadhyay P; Sarkar C
Neurosurgery; 2010 Dec; 67(6):1681-91. PubMed ID: 21107199
[TBL] [Abstract][Full Text] [Related]
29. LGALS3 Is a Poor Prognostic Factor in Diffusely Infiltrating Gliomas and Is Closely Correlated With CD163+ Tumor-Associated Macrophages.
Hu WM; Yang YZ; Zhang TZ; Qin CF; Li XN
Front Med (Lausanne); 2020; 7():182. PubMed ID: 32528967
[No Abstract] [Full Text] [Related]
30. Subgroup characteristics of insular low-grade glioma based on clinical and molecular analysis of 42 cases.
Tang C; Zhang ZY; Chen LC; Sun Z; Zhang Y; Qin Z; Yao Y; Zhou LF
J Neurooncol; 2016 Feb; 126(3):499-507. PubMed ID: 26586262
[TBL] [Abstract][Full Text] [Related]
31. Comprehensive analysis of the expression levels and prognostic values of PRDX family genes in glioma.
Szeliga M
Neurochem Int; 2022 Feb; 153():105256. PubMed ID: 34968631
[TBL] [Abstract][Full Text] [Related]
32. Clinico-neuropathological features of isocitrate dehydrogenase 2 gene mutations in lower-grade gliomas.
Wang LM; Li Z; Piao YS; Cai YN; Zhang LY; Ge HJ; Xu WW; Lu DH
Chin Med J (Engl); 2019 Dec; 132(24):2920-2926. PubMed ID: 31833906
[TBL] [Abstract][Full Text] [Related]
33. Hot spots in dynamic (18)FET-PET delineate malignant tumor parts within suspected WHO grade II gliomas.
Kunz M; Thon N; Eigenbrod S; Hartmann C; Egensperger R; Herms J; Geisler J; la Fougere C; Lutz J; Linn J; Kreth S; von Deimling A; Tonn JC; Kretzschmar HA; Pöpperl G; Kreth FW
Neuro Oncol; 2011 Mar; 13(3):307-16. PubMed ID: 21292686
[TBL] [Abstract][Full Text] [Related]
34. PI3 kinase mutations and mutational load as poor prognostic markers in diffuse glioma patients.
Draaisma K; Wijnenga MM; Weenink B; Gao Y; Smid M; Robe P; van den Bent MJ; French PJ
Acta Neuropathol Commun; 2015 Dec; 3():88. PubMed ID: 26699864
[TBL] [Abstract][Full Text] [Related]
35. Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas.
Sanson M; Marie Y; Paris S; Idbaih A; Laffaire J; Ducray F; El Hallani S; Boisselier B; Mokhtari K; Hoang-Xuan K; Delattre JY
J Clin Oncol; 2009 Sep; 27(25):4150-4. PubMed ID: 19636000
[TBL] [Abstract][Full Text] [Related]
36. NR2F6, a new immune checkpoint that acts as a potential biomarker of immunosuppression and contributes to poor clinical outcome in human glioma.
Miftah H; Naji O; Ssi SA; Ghouzlani A; Lakhdar A; Badou A
Front Immunol; 2023; 14():1139268. PubMed ID: 37575237
[TBL] [Abstract][Full Text] [Related]
37. SHOX2 is a Potent Independent Biomarker to Predict Survival of WHO Grade II-III Diffuse Gliomas.
Zhang YA; Zhou Y; Luo X; Song K; Ma X; Sathe A; Girard L; Xiao G; Gazdar AF
EBioMedicine; 2016 Nov; 13():80-89. PubMed ID: 27840009
[TBL] [Abstract][Full Text] [Related]
38. Prognostic Role of Chicken Ovalbumin Upstream Promoter Transcription Factor II in Isocitrate Dehydrogenase-Mutant Glioma with 1p19q Co-Deletion.
Chai Y; Liu W; Wang C; Rao M; Zhang Y
J Mol Neurosci; 2019 Jun; 68(2):234-242. PubMed ID: 30929126
[TBL] [Abstract][Full Text] [Related]
39. Multigene signature for predicting prognosis of patients with 1p19q co-deletion diffuse glioma.
Hu X; Martinez-Ledesma E; Zheng S; Kim H; Barthel F; Jiang T; Hess KR; Verhaak RGW
Neuro Oncol; 2017 Jun; 19(6):786-795. PubMed ID: 28340142
[TBL] [Abstract][Full Text] [Related]
40. Anatomical location differences between mutated and wild-type isocitrate dehydrogenase 1 in low-grade gliomas.
Yu J; Shi Z; Ji C; Lian Y; Wang Y; Chen L; Mao Y
Int J Neurosci; 2017 Oct; 127(10):873-880. PubMed ID: 27929688
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
